Fig. 1From: DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinomaKaplan-Meier plot: second line progression free survival time with 95 % confidence interval. PFS progression free survivalBack to article page